Genmab — Januar 2020
-
@StockBull Guiding for 2020 kommer vel i forbindelse med årsregnskabet
d. 19 februar? -
Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-2299 and in full pdf https://sci-hub.tw/https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-2299
-
can you read this article in Denmark (it is blocked in NL) https://www.thetelegraph.com/business/article/J-J-looks-to-fend-off-challenges-to-key-drugs-14995067.php
-
No. Maybe one of the guys with VPN?
-
Johnson & Johnson posted weaker-than-expected sales in the final quarter of 2019, raising the stakes for the health-care conglomerate as it banks on new cancer and immunology drugs to replace a group of aging blockbusters.
Some of the company's most lucrative medicines are facing competition from generics and biosimilars. Arthritis drug Remicade's sales fell more than 16% from a year earlier in the quarter, while Zytiga, an older treatment for prostate cancer, saw a nearly 14% decline.
-
At the same time, J&J's storied consumer businesses are also being pressed by upstarts. Sales of its baby-care products declined more than 26% in the U.S. as consumers increasingly look for alternatives to the company's shampoos, lotions and other one-time medicine-cabinet staples.
-
As the company adapts to those changes, it also is confronting increasing political blowback over high drug prices, trade turbulence and a series of lawsuits tied to a range of its products, from opioids to baby powder.
J&J looks to fend off challenges to key drugs, consumer productsRiley Griffin, Bloomberg Published 10:20 am CST, Wednesday, January 22, 2020
Johnson & Johnson Listerine brand mouthwash on Jan. 14, 2020. Photo: Bloomberg Photo By Tiffany Hagler-Geard. / Â
2020 Bloomberg F -
Overall, the New Brunswick, New Jersey-based company reported fourth-quarter revenue of $20.75 billion, just short of the $20.87 billion analysts had expected.
J&J shares declined 0.9% to $147.93 at 10:47 a.m. in New York on Wednesday. They had advanced 16% in the past 12 months through Tuesday's close.
In the year ahead, J&J is likely to draw much of its growth from sales of cancer and immunology drugs. For 2020, adjusted earnings per share are expected to be $8.95 to $9.10. Heading into
-
Horizon Therapeutics Secures U.S. FDA Approval for Teprotumumab, for the Treatment of Thyroid Eye Disease (TED)
Media ReleaseCopenhagen, Denmark, January 23, 2020
·Third Genmab-created product approved by the U.S. FDA
Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted approval to Horizon Therapeutics (Nasdaq: HZNP) for the use of teprotumumab, under the trade name TEPEZZA
(teprotumumab-trbw), for the treatment of Thyroid Eye D -
Wednesday's results, Wall Street analysts had expected $9.09, on average.
Indeed, such drugs were already a bright spot in the fourth quarter. Sales of Stelara, a treatment for psoriasis, jumped 18% to $1.7 billion. Cancer drug Darzalex brought in $830 million in the quarter, up 42% from a year ago.
"Darzalex is transforming the field of multiple myeloma right now," Jan G. J. van de Winkel, the CEO of Danish biotech Genmab, which collaborated with J&J's Janssen unit to develop Darzalex, said
-
in an interview last week. "It's a substantial income driver that any company would be happy about."
Chief Financial Officer Joseph Wolk said J&J is focused on highlighting such best-in-class assets, while potentially shedding those that are growing more slowly.
"We continually look and manage our portfolio in a very rigorous fashion, making sure that we are the best owners of the assets that we have on that," he said on Wednesday. "That works both ways. So we look to complement our portfolio,
-
Gorsky told investors on Wednesday he was "extremely proud overall with the performance of our pharmaceutical group," but was particularly impressed with the immunology vertical's ability to mitigate biosimilar impact on Remicade.
"Despite the mixed results" this quarter, Cantor Fitzgerald analyst Louise Chen said she would continue to recommend J&J "as one of our top ideas in 2020." Chen has an overweight rating on the stock.
-
Concerns about the company's legal exposure have cast a shadow over its shares at times. J&J has been fighting more than 100,000 suits alleging injuries and illnesses caused by its baby powder, opioid painkillers and other products, though it's scored a few wins in the courtroom of late.
The company had about $5.1 billion in litigation expenses in 2019, it said Wednesday, including a $4 billion charge associated with a proposed deal to resolve all claims accusing the company of helping fuel the
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind